Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 12, Issue 6 (2023)

Efficacy of anthelmintics against gastrointestinal nematodes in crossbred dairy cattle

Author(s):
RK Sharma, Ranjan Kumar, Jitendra Prasad, B Shahi and Kaushal Kumar
Abstract:
The present study on- farm trial (OFT) was carried out at Basupatti villages of Muzaffarpur district of Bihar to assess the comparative efficacy of albendazole, fenbendazole and ivermectin against gastrointestinal nematodes in naturally infected crossbred cattle and their correlation with milk production. Forty (40) milking crossbred cattle naturally infected with gastrointestinal nematodes were selected based on faecal examination and randomly divided into four equal groups, each having ten animals. They were designated as F1, F2, F3 and F4. Animals of group one, F1 were kept as untreated control whereas animals of group F2, F3, and F4 were treated with albendazole, fenbendazole and ivermectin at the dose rate of 7.5, 5.0 and 0.2 mg/kg body weight, respectively. The efficacy of each anthelmintic was assessed on the basis of reduction in egg per gram (EPG) in faeces as well as their positive response in the term of increase in milk yield among the animals of treatment groups. It was observed that there were sharp reductions in EPG in the animals of all three treatment groups which came to zero at 14th day and were the same at 28th day as well whereas a gradual increase in EPG was noticed in animals of untreated control group (F1). The reduction in EPG was reflected in terms of increase in milk yield in the animals of the all three treatment groups ranging from 10-13% in 30 days post treatment whereas there was marginal rise is noticed in untreated group as well.
Pages: 1920-1921  |  216 Views  142 Downloads


The Pharma Innovation Journal
How to cite this article:
RK Sharma, Ranjan Kumar, Jitendra Prasad, B Shahi, Kaushal Kumar. Efficacy of anthelmintics against gastrointestinal nematodes in crossbred dairy cattle. Pharma Innovation 2023;12(6):1920-1921.

Call for book chapter